Victoria Aramă *, Violeta Molagic **, Ingrid Linzmeier ***
* Victoria Aramă – Medic primar, șef de lucrări, Clinica I, Institutul de Boli lnfecțioase “Prof Dr. Matei Balș”, București
** Violeta Molagic – rezident Boli lnfecțioase anul V, Institutul de Boli lnfecțioase “Prof Dr. Matei Balș”, București
*** Ingrid Linzmeier – rezident Boli lnfecțioase, anul II, Institutul de Boli lnfecțioase “Prof Dr. Matei Balș”, București
Abstract
In the last decades it was make remarkable progresses in the understanding of the oncogenic potential of EBV and the immune answer anti-EBV. It was shown a better knowledge between EBV and many clinical disorders, the development of laboratory diagnosis and the antiviral treatment. In this paper we make a revue to most recently therapeutic approach in the infectious mononucleosis, Burkitt’s lymphoma, nasopharyngeal carcinoma and EBV-associated post-transplant lymphoproliferative diseases. We insist about the most recent treatment for lymphoproliferative disorders: ,,pre-emptive therapy”, based on the EBV-DNA, monoclonal antibody therapy and passive transfer of cytotoxic T-lymphocytes anti-EBV.